Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$13.81 USD
+1.32 (10.57%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.00 +0.19 (1.38%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
EBS 13.81 +1.32(10.57%)
Will EBS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EBS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EBS
Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?
Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound?
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
Other News for EBS
Emergent BioSolutions launches opioid emergency prepardness campaign
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
Emergent BioSolutions Announces Shelf-Life Extension for NARCAN® Nasal Spray in Canada
Emergent BioSolutions announces shelf-life extension for NARCAN spray in Canada